Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

References

• Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci. 1998;850:251–269.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood. 2000;96(7):2606–2612.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–1146.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD. Management of non-transfusion-dependent thalassemia: A practical guide. Drugs. 2014;74(15):1719–1729.
   PubMed Web of Science ®Google Scholar
• Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027–5035.
   PubMed Web of Science ®Google Scholar
• Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002;282(3):G403–414.
   PubMed Web of Science ®Google Scholar
• Ginzburg Y, Rivella S. Beta-thalassemia: A model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321–4330.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486–489.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Taher A, Cappellini MD. How i treat transfusional iron overload. Blood. 2012;120(18):3657–3669.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Iron overload in non-transfusion-dependent thalassemia: A clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–19.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Wood JC, et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol. 2010;85(4):288–290.
   PubMed Web of Science ®Google Scholar
• Origa R, Barella S, Argiolas GM, et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica. 2008;93(7):1095–1096.
   PubMed Web of Science ®Google Scholar
• Roghi A, Cappellini MD, Wood JC, et al. Absence of cardiac siderosis despite hepatic iron overload in italian patients with thalassemia intermedia: An mri t2* study. Ann Hematol. 2010;89(6):585–589.
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, Gotsis E, Ladis V, et al. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and b-thalassemia major. Int J Cardiovasc Imaging. 2008;24(8):849–854.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the uk: Data from the uk thalassaemia register. Lancet. 2000;355(9220):2051–2052.
   PubMed Web of Science ®Google Scholar
• Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. Br Med J (Clinical Res Ed). 1982;284(6322):1081–1084.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Motta I, Salvatori M, et al. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2012;49(3–4):136–139.
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Cappellini MD, Graziadei G, et al. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Ann Hepatol. 2013;12(1):142–146.
   PubMed Web of Science ®Google Scholar
• Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150(2):245–247.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114–117.
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Musallam KM, Ayache JB, et al. A liver mass in an iron-overloaded thalassaemia intermedia patient. Br J Haematol. 2013;161(1):1.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605–1612.
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26–36.
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent thalassaemia (ntdt). In: Weatherall D, editor. Guidelines for the management of non transfusion dependent thalassaemia (ntdt). Nicosia: Thalassaemia International Federation; 2013.
   Google Scholar
• Guidelines for the management of transfusion dependent thalassaemia (tdt). Cappellini MD, Cohen A, Porter J, et al., editors. Guidelines for the management of transfusion dependent thalassaemia (tdt). Nicosia: Thalassaemia International Federation; 2014.
   Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327–331.
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996;25(2):172–177.
   PubMed Web of Science ®Google Scholar
• Emond MJ, Bronner MP, Carlson TH, et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem. 1999;45(3):340–346.
   PubMed Web of Science ®Google Scholar
• Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol. 1995;23(5):544–549.
   PubMed Web of Science ®Google Scholar
• Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol. 2005;123(1):146–152.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89(4):757–761.
   PubMed Web of Science ®Google Scholar
• Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165–173.
   PubMed Web of Science ®Google Scholar
• Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853–4855.
   PubMed Web of Science ®Google Scholar
• Wood JC, Enriquez C, Ghugre N, et al. Mri r2 and r2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460–1465.
   PubMed Web of Science ®Google Scholar
• St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855–861.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004;126(5):736–742.
   PubMed Web of Science ®Google Scholar
• Saiviroonporn P, Viprakasit V, Sanpakit K, et al. Intersite validations of the pixel-wise method for liver r2* analysis in transfusion-dependent thalassemia patients: A more accessible and affordable diagnostic technology. Hematol Oncol Stem Cell Ther. 2012;5(2):91–95.
   PubMedGoogle Scholar
• Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold t2* mr for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32(2):315–319.
   PubMed Web of Science ®Google Scholar
• Cheng HL, Holowka S, Moineddin R, et al. Liver iron overload assessment by t *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. Am J Hematol. 2012;87(4):435–437.
   PubMed Web of Science ®Google Scholar
• Wood JC. Impact of iron assessment by mri. Hematology. 2011;2011:443–450.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81–85.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, et al. Italian society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741–752.
   PubMed Web of Science ®Google Scholar
• Standards for the clinical care of children and adults with Thalassaemia in the UK [Internet]. United Kingdom Thalassaemia Society; 2008. [cited 2015 Sep 3]. Available from: http://www.hbpinfo.com/ukts-standards-2008.pdf.
   Google Scholar
• Standard-of-care clinical practice guidelines [Internet]; 2012. [cited 2015 Sep 3]. Available from: http://thalassemia.com/treatment-guidelines-5.aspx#gsc.tab=0.
   Google Scholar
• Sayani F, Warner M, Wu J, et al. Guidelines for the clinical care of patients with thalassemia in Canada. Tornonto: Anemia Institute for Research and Education; 2009.
   Google Scholar
• Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J. 2011;41(7):516–524.
   PubMed Web of Science ®Google Scholar
• Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80(5):398–404.
   PubMed Web of Science ®Google Scholar
• L. V. Sur la cristallisation de la ferritine. Bull Soc Chim Biol (Paris). 1937;19:1575–1582.
   Google Scholar
• Lee MH, Means RT Jr.. Extremely elevated serum ferritin levels in a university hospital: Associated diseases and clinical significance. Am J Med. 1995;98(6):566–571.
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood. 2009;114(21):4632–4638.
   PubMed Web of Science ®Google Scholar
• Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346–352.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574–578.
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by r2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329–332.
   PubMed Web of Science ®Google Scholar
• Beaumont C, Simon M, Smith PM, et al. Hepatic and serum ferritin concentrations in patients with idiopathic hemochromatosis. Gastroenterology. 1980;79(5 Pt 1):877–883.
   PubMed Web of Science ®Google Scholar
• Carpenter JP, He T, Kirk P, et al. On t2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519–1528.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac t2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–1968.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Desferal (deferoxamine mesylate) prescribing information. Basel: Novartis Pharmaceuticals; 2011.
   Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (icl670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462.
   PubMed Web of Science ®Google Scholar
• Barry M, Flynn DM, Letsky EA, et al. Long-term chelation therapy in thalassaemia major: Effect on liver iron concentration, liver histology, and clinical progress. Br Med J. 1974;2(5909):16–20.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (cordelia). Blood. 2014;123(10):1447–1454.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
   PubMed Web of Science ®Google Scholar
• Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312(25):1600–1603.
   PubMed Web of Science ®Google Scholar
• Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation. Acta Haematol. 1990;84(3):113–117.
   PubMed Web of Science ®Google Scholar
• Freeman AP, Giles RW, Berdoukas VA, et al. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med. 1983;99(4):450–454.
   PubMed Web of Science ®Google Scholar
• Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95(4):1229–1236.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr. 1989;115(1):151–155.
   PubMed Web of Science ®Google Scholar
• Marcus RE, Davies SC, Bantock HM, et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet. 1984;1(8373):392–393.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using t2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–355.
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in beta-thalassemia intermedia. Birth Defects Orig Artic Ser. 1988;23(5B):29–33.
   PubMedGoogle Scholar
• Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137(3):267–271.
   PubMed Web of Science ®Google Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187–189.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: Combined or monotherapy? The egyptian experience. Ann Hematol. 2008;87(7):545–550.
   PubMed Web of Science ®Google Scholar
• Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferoxamine therapy. J Pediatr. 1990;117(2 Pt 1):326–330.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873.
   PubMed Web of Science ®Google Scholar
• Batey R, Scott J, Jain S, et al. Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol. 1979;22(3):277–279.
   PubMedGoogle Scholar
• Cianciulli P, Sorrentino F, Forte L, et al. Acute renal failure occurring during intravenous desferrioxamine therapy: Recovery after haemodialysis. Haematologica. 1992;77(6):514–515.
   PubMed Web of Science ®Google Scholar
• Koren G, Kochavi-Atiya Y, Bentur Y, et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol. 1991;54(5):371–375.
   PubMed Web of Science ®Google Scholar
• Clajus C, Becker JU, Stichtenoth DO, et al. Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant. 2008;23(3):1061–1064.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology. 2004;14–34.
   PubMedGoogle Scholar
• Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion. 2007;47(10):1919–1929.
   PubMed Web of Science ®Google Scholar
• Piga A, Luzzatto L, Capalbo P, et al. High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur J Haematol. 1988;40(4):380–381.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992;14(1):48–56.
   PubMedGoogle Scholar
• De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr. 1988;113(4):661–669.
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73(3):403–409.
   PubMed Web of Science ®Google Scholar
• Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2(8343):181–184.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Barteselli G, Dell’Arti L, et al. Functional and structural abnormalities in deferoxamine retinopathy: A review of the literature. Biomed Res Int. 2015;2015:249617.
   PubMed Web of Science ®Google Scholar
• Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241–1243.
   PubMed Web of Science ®Google Scholar
• Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: Is it harmful?. Am J Hematol. 1999;60(1):24–26.
   PubMed Web of Science ®Google Scholar
• Traynor K. Deferiprone approved for iron overload. American J Health-Syst Pharm. 2011;68(22):2106.
   Web of Science ®Google Scholar
• Ferriprox: Epar – product information [Internet]; 2009. [cited 2015 Sep 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050.pdf.
   Google Scholar
• Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196–208.
   PubMed Web of Science ®Google Scholar
• Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004;41(1):21–27.
   PubMedGoogle Scholar
• Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (gpo-l-one((r))) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase iii pediatric study (gpo-l-one; a001) from thailand. Am J Hematol. 2013;88(4):251–260.
   PubMed Web of Science ®Google Scholar
• al-Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (l1) in thalassemia major. Blood. 1992;80(3):593–599.
   PubMed Web of Science ®Google Scholar
• Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of l1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82(2):460–466.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol. 2000;108(2):305–312.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Al-R F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91(1):295–300.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339(7):417–423.
   PubMed Web of Science ®Google Scholar
• Pennell D. Mri and iron-overload cardiomyopathy in thalassaemia. Circulation. 2006;113(11):f43–44.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599–1606.
   PubMed Web of Science ®Google Scholar
• Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from hong kong. Hemoglobin. 2006;30(2):263–274.
   PubMed Web of Science ®Google Scholar
• Fisher CA, Premawardhena A, de Silva S, et al. The molecular basis for the thalassaemias in sri lanka. Br J Haematol. 2003;121(4):662–671.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–3737.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica. 2003;88(5):489–496.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Carpenter JP, Roughton M, et al. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the italian society for thalassemia and hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247–251.
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: A clinical observational study. J Cardiovasc Magn Reson. 2009;11:20.
   PubMed Web of Science ®Google Scholar
• Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (l1). Haematologica. 2000;85(2):115–117.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin e patients in thailand. Br J Haematol. 2003;122(2):305–310.
   PubMed Web of Science ®Google Scholar
• Calvaruso G, Vitrano A, Di Maggio R, et al. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term italian multicenter randomized clinical trial. Am J Hematol. 2015;90(7):634–638.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. Ferriprox: EPAR – Product Information; 2013. [cited 2015 Sep 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050.pdf.
   Google Scholar
• Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in italian patients. Br J Haematol. 2002;118(1):330–336.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wonke B, Wickens DG, et al. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol. 1994;47(7):657–660.
   PubMed Web of Science ®Google Scholar
• Wu SF, Peng CT, Wu KH, et al. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin. 2006;30(2):215–218.
   PubMed Web of Science ®Google Scholar
• Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002;100(5):1566–1569.
   PubMed Web of Science ®Google Scholar
• Taher A, Aoun E, Sharara AI, et al. Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol. 2004;112(4):179–183.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583–1587.
   PubMed Web of Science ®Google Scholar
• Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol. 2005;74(3):217–220.
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Marwaha RK, Das RR. Long-term response to deferiprone therapy in asian indians. Ann Hematol. 2010;89(2):135–140.
   PubMed Web of Science ®Google Scholar
• Jamuar SS, Lai AH, Tan AM, et al. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. J Paediatr Child Health. 2011;47(11):812–817.
   PubMed Web of Science ®Google Scholar
• Elalfy M, Wali YA, Qari M, et al. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. Pediatr Blood Cancer. 2014;61(5):879–884.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy AM, El-Alfy MS, Sari TT, et al. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. Eur J Haematol. 2014;92(4):337–340.
   PubMed Web of Science ®Google Scholar
• Tondury P, Zimmermann A, Nielsen P, et al. Liver iron and fibrosis during long-term treatment with deferiprone in swiss thalassaemic patients. Br J Haematol. 1998;101(3):413–415.
   PubMed Web of Science ®Google Scholar
• Kellenberger CJ, Schmugge M, Saurenmann T, et al. Radiographic and mri features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. AJR Am J Roentgenol. 2004;183(4):989–994.
   PubMed Web of Science ®Google Scholar
• Beau-Salinas F, Guitteny MA, Donadieu J, et al. High doses of deferiprone may be associated with cerebellar syndrome. BMJ (Clinical Research Ed). 2009;338:a2319.
   PubMed Web of Science ®Google Scholar
• Parakh N, Sharma R, Prakash O, et al. Neurological complications and cataract in a child with thalassemia major treated with deferiprone. J Pediatr Hematol Oncol. 2015;37(7):e433–e434.
   PubMed Web of Science ®Google Scholar
• Genc GE, Ozturk Z, Gumuslu S, et al. Mineral levels in thalassaemia major patients using different iron chelators. Biol Trace Elem Res. 2015. [Epub ahead of print].
   PubMedGoogle Scholar
• Novartis Pharmaceuticals. Deferasirox prescribing infromation. Basel: Novartis Pharmaceuticals; 2013.
   Google Scholar
• Shirley M, Plosker GL. Deferasirox: A review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Drugs. 2014;74(9):1017–1027.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Giardina PJ, Chirnomas D, et al. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60(9):1507–1512.
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (icl670): A 1-yr prospective study. Eur J Haematol. 2008;80(2):168–176.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The escalator study. Eur J Haematol. 2009;82(6):458–465.
   PubMed Web of Science ®Google Scholar
• Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752–759.
   PubMed Web of Science ®Google Scholar
• Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011;141(4):1202-1211, 1211.e1201-1203.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective epic study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566.
   PubMed Web of Science ®Google Scholar
• Porter JB, Elalfy MS, Taher AT, et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the epic magnetic resonance imaging substudy. Ann Hematol. 2013;92(2):211–219.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial t2* in patients with beta-thalassemia major. Haematologica. 2012;97(6):842–848.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Highlights of prescribing information [Internet]. 2011. [cited 2015 Sep 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021882s012lbl.pdf.
   Google Scholar
• Yadav SK, Gupta V, El Kohly A, et al. Perforated duodenal ulcer: A rare complication of deferasirox in children. Indian J Pharmacol. 2013;45(3):293–294.
   PubMed Web of Science ®Google Scholar
• Huang WF, Chou HC, Tsai YW, et al. Safety of deferasirox: A retrospective cohort study on the risks of gastrointestinal, liver and renal events. Pharmacoepidemiol Drug Saf. 2014;23(11):1176–1182.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Taher A. Long-term experience with deferasirox (icl670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391–2402.
   PubMed Web of Science ®Google Scholar
• Diaz-Garcia JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, et al. Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol. 2014;10(10):574–586.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years’ follow-up. Blood. 2011;118(4):884–893.
   PubMed Web of Science ®Google Scholar
• Economou M, Printza N, Teli A, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010;123(3):148–152.
   PubMed Web of Science ®Google Scholar
• Quinn CT, Johnson VL, Kim HY, et al. Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153(1):111–117.
   PubMed Web of Science ®Google Scholar
• Chuang GT, Tsai IJ, Tsau YK, et al. Transfusion-dependent thalassemic patients with renal fanconi syndrome due to deferasirox use. Nephrology (Carlton, Vic). 2015.
   PubMed Web of Science ®Google Scholar
• Grange S, Bertrand DM, Guerrot D, et al. Acute renal failure and fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25(7):2376–2378.
   PubMed Web of Science ®Google Scholar
• Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54(5):931–934.
   PubMed Web of Science ®Google Scholar
• Murphy N, Elramah M, Vats H, et al. A case report of deferasirox-induced kidney injury and fanconi syndrome. WMJ. 2013;112(4):177–180.
   PubMedGoogle Scholar
• Rheault MN, Bechtel H, Neglia JP, et al. Reversible fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674–676.
   PubMed Web of Science ®Google Scholar
• Wei HY, Yang CP, Cheng CH, et al.. Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion. 2011;51(5):949–954.
   PubMed Web of Science ®Google Scholar
• Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32(7):564–567.
   PubMed Web of Science ®Google Scholar
• Meerpohl JJ, Antes G, Rucker G, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2012;2:CD007476.
   PubMedGoogle Scholar
• Pan Y, Keane PA, Sadun AA, et al. Optical coherence tomography findings in deferasirox-related maculopathy. Retin Cases Brief Rep. 2010;4(3):229–232.
   PubMedGoogle Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (ntdt) patients: 1-year extension results from the thalassa study. Ann Hematol. 2013;92(11):1485–1493.
   PubMed Web of Science ®Google Scholar
• Grandvuillemin A, Audia S, Leguy-Seguin V, et al. [severe thrombocytopenia and mild leucopenia associated with deferasirox therapy]. Therapie. 2009;64(6):405–407.
   PubMed Web of Science ®Google Scholar
• Anastasi S, Lisi R, Abbate G, et al. Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient. Pediatr Endocrinol Rev. 2011;8(Suppl 2):345–347.
   PubMedGoogle Scholar
• Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: A consensus statement from the american heart association. Circulation. 2013;128(3):281–308.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Piga A, et al. Sustained improvements in myocardial t2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015;90(2):91–96.
   PubMed Web of Science ®Google Scholar
• Casale M, Citarella S, Filosa A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with beta-thalassemia major. Am J Hematol. 2014;89(12):1102–1106.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909–917.
   PubMed Web of Science ®Google Scholar
• Porter J, Bowden DK, Economou M, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial. Anemia. 2012;2012(297641).
   PubMedGoogle Scholar
• Grady RW, Galanello R, Randolph RE, et al. Toward optimizing the use of deferasirox: Potential benefits of combined use with deferoxamine. Haematologica. 2013;98(1):129–135.
   PubMed Web of Science ®Google Scholar
• Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50(2):99–104.
   PubMed Web of Science ®Google Scholar
• Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014;53(3):164–167.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Kattamis A, Cappellini MD, et al. Deferasirox–deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (hyperion). 55th ASH annual meeting; 2013 Dec 8; New Orleans, LA.
   Google Scholar
• Lai ME, Grady RW, Vacquer S, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45(2):136–139.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.
   PubMed Web of Science ®Google Scholar
• Totadri S, Bansal D, Bhatia P, et al. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: A prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62(9):1592–1596.
   PubMed Web of Science ®Google Scholar
• Phase ii study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) [Internet]. [cited 2015 Sep 3]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02125877?term=Deferasirox&rank=30
   Google Scholar
• Pilot study of the pharmacokinetic profile of a single dose of deferiprone sustained-release formulation in healthy volunteers [Internet]. [cited 2015 Sep 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02189941?term=deferiprone&rank=5
   Google Scholar
• Absorption, metabolism, and excretion of a single dose of ferriprox® in patients with sickle cell disease [Internet]. [cited 2015 Sep 3]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01835496?term=deferiprone&rank=9
   Google Scholar
• Chuansumrit A, Songdej D, Sirachainan N, et al. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: A 1-year experience. Paediatr Int Child Health. 2015. 2046905515Y0000000040
   Google Scholar
• ElAlfy MS, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601–605.
   PubMed Web of Science ®Google Scholar
• Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010;120(12):4466–4477.
   PubMed Web of Science ®Google Scholar
• Guo S, Casu C, Gardenghi S, et al. Reducing tmprss6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013;123(4):1531–1541.
   PubMed Web of Science ®Google Scholar
• Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177–182.
   PubMed Web of Science ®Google Scholar
• Suragani RN, Cawley SM, Li R, et al. Modified activin receptor iib ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood. 2014;123(25):3864–3872.
   PubMed Web of Science ®Google Scholar
• Dussiot M, Maciel TT, Fricot A, et al. An activin receptor iia ligand trap corrects ineffective erythropoiesis in beta-thalassemia. 2014;20(4):398–407
   Google Scholar